Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET

Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET

Abstract Background Radiotherapy delivery regimens can vary between a single fraction (SF) and multiple fractions (MF) given daily for up to several weeks depending on the location of the cancer or metastases. With limited evidence comparing fractionation regimens for oligometastases, there is suppo...

Full description

Bibliographic Details
Main Authors: Robert Olson, Hadassah Abraham, Curtis Leclerc, Alexander Benny, Sarah Baker, Quinn Matthews, Nick Chng, Alanah Bergman, Benjamin Mou, Emma M. Dunne, Devin Schellenberg, Will Jiang, Elisa Chan, Siavash Atrchian, Shilo Lefresne, Hannah Carolan, Boris Valev, Scott Tyldesley, Andrew Bang, Tanya Berrang, Haley Clark, Fred Hsu, Alexander V. Louie, Andrew Warner, David A. Palma, Doris Howell, Aisling Barry, Laura Dawson, Petra Grendarova, Debra Walker, Rishi Sinha, Jillian Tsai, Houda Bahig, Isabelle Thibault, Rashmi Koul, Sashendra Senthi, Iain Phillips, Derek Grose, Paul Kelly, John Armstrong, Ronan McDermott, Candice Johnstone, Srini Vasan, Noel Aherne, Stephen Harrow, Mitchell Liu
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Subjects:
Stereotactic ablative radiotherapy
Oligometastases
Quality of Life
Survival
Cancer
Single Fraction
Online Access:https://doi.org/10.1186/s12885-024-11905-7

Internet

https://doi.org/10.1186/s12885-024-11905-7

Similar Items